The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 28, 2018

Filed:

Nov. 14, 2016
Applicant:

Symphogen A/s, Ballerup, DK;

Inventors:

Johan Lantto, Lund, SE;

Kim Vilbour Andersen, Brønshøj, DK;

Peter Sejer Andersen, Vanløse, DK;

Magnus Strandh, Malmö, SE;

Klaus Koefoed, København S, DK;

Lars Søgaard Nielsen, Nivå, DK;

Mikkel Wandahl Pedersen, Alleroed, DK;

Helle Jacobsen, Virum, DK;

Michael Kragh, Copenhagen, DK;

Ida Kjaer, Copenhagen, DK;

Thomas Tuxen Poulsen, Dyssegaard, DK;

Assignee:

Symphogen A/S, Ballerup, DK;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/32 (2006.01); C07K 16/30 (2006.01); A61K 47/48 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/39558 (2013.01); A61K 47/486 (2013.01); A61K 47/48384 (2013.01); A61K 47/48569 (2013.01); C07K 16/30 (2013.01); C07K 16/303 (2013.01); C07K 16/32 (2013.01); A61K 2039/507 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/56 (2013.01); C07K 2317/76 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01);
Abstract

The invention relates to humanized recombinant antibodies targeting the EGFR family receptors EGFR, HER2 and HER3, compositions comprising at least one humanized anti-EGFR antibody, at least one humanized anti-HER2 antibody and at least one humanized anti-HER3 antibody, and use of the antibody compositions for treatment of cancer. The invention also relates to the use of antibodies targeting multiple EGFR-family receptors to treat cancer (e.g., pancreatic cancer) and cancer that has acquired resistance to previous therapies.


Find Patent Forward Citations

Loading…